Join Massive Bio at the ASCO Annual Meeting 2026

“This publication draws a line. We are no longer debating whether AI can work in oncology clinical trial matching. We are demonstrating how it works, at scale, in routine practice, with transparent and auditable results. The architecture matters as much as the outcomes: neuro-symbolic, multi-agent systems grounded in domain-specific knowledge graphs are the infrastructure layer oncology has been missing. This is how we begin to close the gap where only 3%-5% of cancer patients access clinical trials, not because trials do not exist, but because we have failed to operationalize matching at the speed and complexity the disease demands.”

Arturo Loaiza-Bonilla, MD, MSEd, FACP
Co-Founder and Chief Medical AI Officer, Massive Bio

“At Massive Bio, our mission goes beyond conventional approaches—we use AI-powered technology to connect cancer patients with clinical trials that fit their unique profiles. By supporting oncologists, patients, and sponsors with real-time insights and streamlined processes, we help accelerate clinical research and expand access. Our goal is simple: ensure that every patient, regardless of location or background, has timely access to the most relevant clinical trial options.”

Selin Kurnaz, PhD,
Co-founder and CEO of Massive Bio

“Building AI that performs well in a controlled setting is a solved problem. Building AI that performs reliably across thousands of patients with fragmented, incomplete, and heterogeneous clinical data, that is the engineering challenge this paper addresses. Our three-agent architecture was designed from the ground up to handle the scale, complexity, and safety requirements of real-world oncology. The knowledge graph is not an add-on; it is the backbone that makes the system auditable, deterministic where it must be, and resilient to the noise that defines real clinical data.”

Çağatay M. Çulcuoğlu
Co-Founder, Chief Technology Officer and Chief Operating Officer, Massive Bio